| Abstract |
We studied 26 patients in a randomized, placebo-controlled, double-blind parallel trial to evaluate the efficacy and safety of donepezil in chronic poststroke aphasia. Donepezil (10 mg/day) improved aphasia severity at endpoint (week 16) relative to placebo (p = 0.037). |
| Authors | M L Berthier, C Green, C Higueras, I Fernández, J Hinojosa, M C Martín |
| Journal | Neurology
(Neurology)
Vol. 67
Issue 9
Pg. 1687-9
(Nov 14 2006)
ISSN: 1526-632X [Electronic] United States |
| PMID | 17101908
(Publication Type: Journal Article, Randomized Controlled Trial)
|
| Chemical References |
- Indans
- Nootropic Agents
- Piperidines
- Placebos
- Donepezil
- Acetylcholine
|
| Topics |
- Acetylcholine
(metabolism)
- Adult
- Aphasia
(drug therapy, etiology, physiopathology)
- Brain
(blood supply, drug effects, physiopathology)
- Cerebrovascular Circulation
(drug effects, physiology)
- Donepezil
- Double-Blind Method
- Female
- Humans
- Indans
(administration & dosage)
- Language Tests
- Male
- Middle Aged
- Nerve Regeneration
(drug effects, physiology)
- Neural Pathways
(blood supply, drug effects, physiopathology)
- Neuronal Plasticity
(drug effects, physiology)
- Nootropic Agents
(administration & dosage)
- Piperidines
(administration & dosage)
- Placebos
- Recovery of Function
(drug effects, physiology)
- Speech Therapy
- Stroke
(complications, physiopathology)
- Treatment Outcome
|
